How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/staphylococcus-aureus-otitis-externa.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Staphylococcus Aureus Otitis Externa — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Staphylococcus Aureus Otitis Externa (disease) competitive landscape: 6 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

6 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Staphylococcus Aureus Otitis Externa, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Cipro	ciprofloxacin	Bayer AG	Fluoroquinolone antibiotic	DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A	1987-10-22
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
Cortisol	Cortisol	University of Zurich		Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible
Ofloxacine	Ofloxacine	Assistance Publique - Hôpitaux de Paris		Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1
Ciprofloxacine	Ciprofloxacine	Poitiers University Hospital		DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 3 drugs in Staphylococcus Aureus Otitis Externa
Assistance Publique - Hôpitaux de Paris · 1 drug in Staphylococcus Aureus Otitis Externa
Bayer AG · 1 drug in Staphylococcus Aureus Otitis Externa
Generic (originally Merck) · 1 drug in Staphylococcus Aureus Otitis Externa
Generic (originally Merck/Upjohn) · 1 drug in Staphylococcus Aureus Otitis Externa
Poitiers University Hospital · 1 drug in Staphylococcus Aureus Otitis Externa
University of Zurich · 1 drug in Staphylococcus Aureus Otitis Externa

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Staphylococcus Aureus Otitis Externa:

Cite this brief

Drug Landscape (2026). Staphylococcus Aureus Otitis Externa — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/staphylococcus-aureus-otitis-externa. Accessed 2026-06-10.

Staphylococcus Aureus Otitis Externa full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing